Title |
miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression
|
---|---|
Published in |
Journal of Molecular Medicine, May 2017
|
DOI | 10.1007/s00109-017-1539-z |
Pubmed ID | |
Authors |
Xiaojie Xu, Shuai Jin, Yongfu Ma, Zhongyi Fan, Zhifeng Yan, Wenchao Li, Qi Song, Wenye You, Zhaohui Lyu, Yeqiong Song, Pingan Shi, Ying Liu, Xiao Han, Ling Li, Ying Li, Yang Liu, Qinong Ye |
Abstract |
Lung cancer remains the leading cause of cancer-related death worldwide. Paclitaxel, either as monotherapy or combined with other agents, is the standard treatment for advanced non-small cell lung cancer (NSCLC), the most common type of lung cancer. However, both de novo and acquired resistance against paclitaxel frequently occurs and represents a huge clinical problem. The underlying mechanisms remain poorly characterized. Here, by comparing microRNA (miRNA) expression levels using miRNA arrays, we observed differential expression of miR-30a-5p in two independent lung cancer cell pairs (paclitaxel-resistant vs paclitaxel-sensitive A549 cell lines). Overexpression of miR-30a-5p sensitizes NSCLC cells to paclitaxel both in vitro and in vivo. In addition, miR-30a-5p increases paclitaxel sensitivity by promoting chemotherapy-induced apoptosis via downregulating BCL-2, a key apoptosis regulator. High miR-30a-5p expression is positively correlated with enhanced responsiveness to paclitaxel and predicts a more favorable clinical outcome in NSCLC patients. Moreover, miR-30a-5p expression is negatively correlated with BCL-2 expression in NSCLC tissues. These data indicate that miR-30a-5p may be useful to treat paclitaxel-resistant lung cancer and may also provide a biomarker to predict paclitaxel responsiveness in lung cancer. BCL-2 is a novel direct target of miR-30a-5p. miR-30a-5p enhances NSCLC paclitaxel sensitivity in vitro and in vivo. miR-30a-5p sensitizes NSCLC cells to paclitaxel by inducing apoptosis through BCL-2 inhibition. miR-30a-5p negatively correlates with BCL-2 and predicts a favorable clinical outcome in NSCLC patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 22 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 2 | 9% |
Student > Bachelor | 2 | 9% |
Student > Ph. D. Student | 2 | 9% |
Student > Doctoral Student | 1 | 5% |
Other | 1 | 5% |
Other | 4 | 18% |
Unknown | 10 | 45% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 18% |
Medicine and Dentistry | 4 | 18% |
Unspecified | 1 | 5% |
Nursing and Health Professions | 1 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Other | 2 | 9% |
Unknown | 9 | 41% |